Basit öğe kaydını göster

dc.contributor.authorTuzun, Erdem
dc.contributor.authorUlusoy, Canan
dc.contributor.authorGencer, Mehmet
dc.contributor.authorCoban, Arzu
dc.contributor.authorVural, Burçak
dc.contributor.authorTURKOGLU, Recai
dc.contributor.authorEKMEKCI, Duygu
dc.contributor.authorErdag, Ece
dc.contributor.authorHaytural, Hazal
dc.contributor.authorKucukerden, Melike
dc.contributor.authorYalcinkaya, Nazli
dc.contributor.authorAkbas-Demir, Deniz
dc.contributor.authorCavus, Filiz
dc.contributor.authorTuran, Selin
dc.contributor.authorSehitoglu, Elcin
dc.date.accessioned2021-03-03T09:15:04Z
dc.date.available2021-03-03T09:15:04Z
dc.date.issued2014
dc.identifier.citationTURKOGLU R., Gencer M., EKMEKCI D., Ulusoy C., Erdag E., Sehitoglu E., Cavus F., Haytural H., Kucukerden M., Yalcinkaya N., et al., "Switch-Associated Protein 70 Antibodies in Multiple Sclerosis: Possible Association with Disease Progression", MEDICAL PRINCIPLES AND PRACTICE, cilt.23, sa.3, ss.239-245, 2014
dc.identifier.issn1011-7571
dc.identifier.othervv_1032021
dc.identifier.otherav_1c0dcaee-f463-45c1-9bbf-1aa5b5e7674f
dc.identifier.urihttp://hdl.handle.net/20.500.12627/24098
dc.identifier.urihttps://doi.org/10.1159/000358221
dc.description.abstractObjective: This study was conducted to identify a biomarker for multiple sclerosis (MS) that can be used as a predictor of relapse and disability. Materials and Methods: Sera of 26 consecutive relapsing-remitting MS (RRMS) patients were screened for switch-associated protein 70 (SWAP-70) antibody, which was previously identified by protein macroarray. The serum levels of several cytokines, chemokines and soluble adhesion molecules related to MS attacks were measured by enzyme-linked immunosorbent assay (ELISA). A possible correlation was sought among levels of SWAP-70 antibody, measured humoral factors and disability scores. Results: ELISA studies showed high-titre SWAP-70 antibodies in 16 (61.5%) RRMS sera obtained during the attack period and 9 (34.6%) sera obtained during remission. There was a significant inverse correlation between SWAP-70 antibody levels and expanded disability status scale scores, CXCL10, soluble VCAM-1, CXCL13 and soluble VLA-4 levels. Conclusion: Our results showed that SWAP-70 antibodies could potentially be utilized as relapse and prognostic biomarkers in MS. Whether or not SWAP-70 antibodies have any effect on disease mechanisms requires further investigation. (C) 2014 S. Karger AG, Basel
dc.language.isoeng
dc.subjectTemel Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, GENEL & İÇECEK
dc.titleSwitch-Associated Protein 70 Antibodies in Multiple Sclerosis: Possible Association with Disease Progression
dc.typeMakale
dc.relation.journalMEDICAL PRINCIPLES AND PRACTICE
dc.contributor.departmentIstanbul Haydarpasa Numune Training & Research Hospital , ,
dc.identifier.volume23
dc.identifier.issue3
dc.identifier.startpage239
dc.identifier.endpage245
dc.contributor.firstauthorID2169


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster